文献速递临床试验与 GCP流行病学与生物统计

羟氯喹暴露前预防用于COVID-19疫情期间高风险医护人员的多中心双盲随机对照试验方案结构化摘要

Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.
PubMed 文献 · Trials · 2020-07-29

该研究为多中心、双盲、平行设计(1:1)随机对照试验,计划纳入约440名西班牙四家医院的高风险医护人员,评估羟氯喹暴露前预防(PrEP)相比安慰剂在6个月内降低COVID-19发病风险的有效性,并评估安全性、SARS-CoV-2血清转换率等次要终点。截至2020年6月2日已招募275名参与者,因全国疫情曲线下降未达预计样本量,研究已于6月26日暂停。

要点

  • 羟氯喹PrEP方案为前4天每日400mg,随后每周400mg,持续6个月。
  • 主要终点为随访6个月内PCR确诊或症状兼容且血清转换的COVID-19病例数。
  • 截至2020年6月2日已入组275人,未达计划440人,研究因疫情下降暂停。

核心结论

  • 该方案旨在评估羟氯喹暴露前预防能否降低高风险医护人员COVID-19发病风险,目前研究暂停,尚无疗效结论。

研究设计与样本

  • 多中心、双盲、平行设计(1:1)随机对照试验,计划纳入约440名西班牙四家医院的高风险医护人员。
  • 参与者为18岁及以上、每周至少在医院工作3天、SARS-CoV-2 PCR和血清学快速诊断检测均为阴性的医护人员。
  • 排除标准包括妊娠、哺乳、正在使用抗病毒药/抗逆转录病毒药/皮质类固醇、过去一个月使用氯喹或羟氯喹、或任何羟氯喹禁忌症。
  • 采用简单随机化(计算机生成随机数)分配至干预组或对照组,参与者、照护医生和护士、结果评估研究者均设盲。

主要发现

  • 截至2020年6月2日方案版本1.5,已招募275名参与者并完成首月随访。
  • 因全国疫情曲线下降,预计样本量未能达到,截至该日期纳入总数为275人。
  • 研究已于6月26日暂停,等待新的疫情曲线出现。

关键数值与推荐

  • 干预组:标准治疗基础上,前4天每日口服400mg羟氯喹(2片200mg Dolquine®),随后每周400mg,持续6个月。
  • 对照组:安慰剂片外观与200mg羟氯喹(Dolquine®)片相同,按相同方案服用。
  • 主要终点:随访6个月内,第0天SARS-CoV-2 PCR和血清学阴性的医护人员中,PrEP组相比安慰剂组的COVID-19确诊病例数(PCR阳性或症状兼容且血清转换)。
  • 次要终点包括:第0天血清学阴性者6个月内SARS-CoV-2血清转换率、羟氯喹相关不良事件、非PrEP组SARS-CoV-2感染和COVID-19发病率、不同临床/分析/微生物条件的风险比、血清样本库。
  • 两组均鼓励按照现行医院指南使用个人防护装备(PPE)预防COVID-19。

临床怎么用

  • 该研究为方案摘要,尚未提供羟氯喹PrEP有效性的临床实践推荐。
  • 高风险医护人员仍应按现行医院指南使用个人防护装备预防COVID-19。

局限性

  • 截至摘要日期,预计样本量未达到,实际纳入275人而非计划的440人。
  • 研究因全国疫情曲线下降而暂停,尚未恢复。
  • 摘要未报告主要终点或次要终点的结果数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study is to assess the efficacy of the use of pre-exposure prophylaxis (PrEP) with hydroxychloroquine against placebo in healthcare workers with high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in reducing their risk of coronavirus disease 2019 (COVID-19) disease during an epidemic period. As secondary objectives, we would like to: i) assess the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2 (defined by seroconversion) during an epidemic period, ii) evaluate the safety of PrEP with hydroxychloroquine in adults, iii) describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 infection, iv) identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high risk of SARS-CoV-2 infection, v) set up a repository of serum samples obtained from healthcare workers at high risk of SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection. TRIAL DESIGN: Multicentre double-blind parallel design (ratio 1:1) randomized controlled clinical trial. PARTICIPANTS: Approximately 440 healthcare workers of four Spanish hospitals (Hospital Clínic of Barcelona, Hospital de la Santa Creu i Sant Pau of Barcelona, Hospital Plató of Barcelona, Hospital General de Granollers, Barcelona) will be recruited. Participants are considered to be at high-risk of SARS-CoV-2 infection due to their frequent contact with suspected and confirmed cases of COVID-19. For eligibility, healthcare workers with 18 years old or older working at least 3 days a week in a hospital with both negative SARS-CoV-2 polymerase chain reaction (PCR) assays and serological COVID-19 rapid diagnostic tests (RDT) are invited to participate. Participants with any of the following conditions are excluded: pregnancy, breastfeeding, ongoing antiviral, antiretroviral or corticosteroids treatment, chloroquine or hydroxychloroquine uptake the last month or any contraindication to hydroxychloroquine treatment. INTERVENTION AND COMPARATOR: Eligible participants will be allocated to one of the two study groups: Intervention group (PrEP): participants will receive the standard of care and will take 400mg of hydroxychloroquine (2 tablets of 200 mg per Dolquine® tablet) daily the first four consecutive days, followed by 400 mg weekly for a period of 6 months. CONTROL GROUP: participants will receive placebo tablets with identical physical appearance to hydroxychloroquine 200 mg (Dolquine®) tablets following the same treatment schedule of the intervention group. Both groups will be encouraged to use the personal protection equipment (PPE) for COVID-19 prevention according to current hospital guidelines. MAIN OUTCOMES: The primary endpoint will be the number of confirmed cases of a COVID-19 (defined by a positive PCR for SARS-CoV-2 or symptoms compatible with COVID-19 with seroconversion) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative SARS-CoV-2 PCR and serology at day 0. As secondary endpoints, we will obtain: i) the SARS-CoV-2 seroconversion in the PrEP group compared to placebo during the 6 months of follow-up in healthcare workers with negative serology at day 0; ii) the occurrence of any adverse event related with hydroxychloroquine treatment; iii) the incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers in the non-PrEP group, among the total of healthcare workers included in the non-PrEP group during the study period; iv) the risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19; v) a repository of serum samples obtained from healthcare workers confirmed COVID-19 cases for future research on blood markers to predict SARS-CoV-2 infection. RANDOMISATION: Participants meeting all eligibility requirements will be allocated to one of the two study arms (PrEP with hydroxychloroquine or non-PrEP control group) in a 1:1 ratio using simple randomisation with computer generated random numbers. BLINDING (MASKING): Participants, doctors and nurses caring for participants, and investigators assessing the outcomes will be blinded to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Each intervention group will have 220 participants, giving a total of 440 participants. TRIAL STATUS: The current protocol version is 1.5, 2nd of June 2020. Two hundred and seventy-fiveparticipants were recruited and completed first month follow-up until date. The estimated sample size could not be reached yet due to the declining national epidemic curve. Thus, 275 is the total number of participants included until date. The study has been suspended (26th of June) until new epidemic curve occurs. TRIAL REGISTRATION: This trial was registered on April 2nd 2020 at clinicaltrials.gov with the number NCT04331834. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Grau-Pujol B, Camprubí D, Marti-Soler H, et al. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial. Trials. 2020. PMID: 32727613. doi:10.1186/s13063-020-04621-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。